256 related articles for article (PubMed ID: 12164480)
1. Engineering antibodies for therapy.
Presta LG
Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
4. Towards an immunotherapy for p185HER2 overexpressing tumors.
Carter P; Rodrigues ML; Lewis GD; Figari I; Shalaby MR
Adv Exp Med Biol; 1994; 353():83-94. PubMed ID: 7985544
[No Abstract] [Full Text] [Related]
5. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
7. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
9. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
10. [Engineering Antibodies as Drugs: Principles and Practice].
Lugovskoy AA
Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
[TBL] [Abstract][Full Text] [Related]
11. Engineering antibodies for therapy.
Adair JR
Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872
[TBL] [Abstract][Full Text] [Related]
12. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
13. Toward Drug-Like Multispecific Antibodies by Design.
Sawant MS; Streu CN; Wu L; Tessier PM
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
15. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic roles for antibody mixtures.
Raju TS; Strohl WR
Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
[TBL] [Abstract][Full Text] [Related]
17. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
Teillaud JL
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin isotype knowledge and application to Fc engineering.
Brezski RJ; Georgiou G
Curr Opin Immunol; 2016 Jun; 40():62-9. PubMed ID: 27003675
[TBL] [Abstract][Full Text] [Related]
19. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
Wels W; Groner B; Hynes NE
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
[No Abstract] [Full Text] [Related]
20. Diabodies: small bispecific antibody fragments.
Holliger P; Winter G
Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
